Share This Post

New Kidney Cancer Drug Beats Standard Therapy

From Science Daily:

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute. Individuals who received the drug, cabozantinib, had a longer time to progression — the interval before their cancer worsened — than those taking sunitinib (Sutent), the drug that has been the standard initial treatment for metastatic kidney cancer for the past decade.

Read the full article.

Share This Post

Lost Password


Subscribe for updates!